CorVista Raises Equity Capital

• TM Capital advised CorVista Health, Inc. in raising $65 million of Series C equity capital to advance its artificial intelligence-based cardiovascular diagnostic technology, bringing the Company’s total funding to nearly $100 million
• CorVista’s non-invasive point-of-care solution utilizes cloud-based algorithms, enabling physicians to rapidly test for heart disease without the need for radiation, contrast agents or cardiac stress
• Proceeds will be used for acceleration of product development and infrastructure ahead of commercialization, as well as ongoing clinical research to assess coronary artery disease, heart failure and pulmonary hypertension
• The financing was led by Ambix Life Science Fund I, L.P., along with MedVenture Partners, Inc. and several new and previous investors
• TM Capital also advised CorVista (previously known as Analytics 4 Life) on its $25.6 million Series B financing

Read the full press release